Over a six-week stretch in spring 2026, OpenAI rebuilt what its Codex product actually is. On April 16, the company released a major Codex update titled “Codex for (almost) everything,” ...

Solidity remains the dominant smart contract language for Ethereum and EVM-compatible chains, with the 2025 developer survey collecting responses from developers across eighty-seven different ...

A multi-stage attack on Linux devices began with an exposed F5 BIG-IP edge appliance and pivoted to an internal Confluence ...

A research team at Mohamed bin Zayed University of Artificial Intelligence published a finding in April 2026 that has gained traction in engineering circles for reasons that go beyond its headline ...

GitHub confirmed attackers stole 3,800 internal repositories via a poisoned VS Code extension. The same threat group, TeamPCP ...

Phishing campaigns continue to improve sophistication and refinement in blending social engineering, delivery and hosting infrastructure, and authentication abuse to remain effective against evolving ...

If you’ve ever wished your code reviews were more thorough than a quick lint pass, Ultrareview might be exactly what you’re looking for. Built into Claude Code, Ultrareview is a premium slash command ...

Cursor announced Thursday the launch of Cursor 3, a new product interface that allows users to spin up AI coding agents to complete tasks on their behalf. The product, which was developed under the ...

VentureBeat made with Google Gemini 3.1 Pro Image Anthropic appears to have accidentally revealed the inner workings of one of its most popular and lucrative AI products, the agentic AI harness Claude ...

Claude Code 2.0 as it has been labelled by some introduces new features aimed at improving coding workflows and handling complex tasks more effectively. One notable addition is the “By the Way” ...

Code reviews are a critical part of modern software development, yet they can often become bottlenecks, especially when dealing with large or complex pull requests (PRs). Anthropic has this week ...

The FDA is reviewing iberdomide for relapsed or refractory multiple myeloma, with a decision date set for August. The U.S. Food and Drug Administration (FDA) has accepted a new drug application for ...